Anthropic introduced Claude Science AI model to accelerate scientific research and drug development

American startup Anthropic presented a new specialized model Claude Science, developed to help scientists find ways to combat diseases and create medicines faster.

Why Biotech and Pharma Are a Priority Area for AI

Biotechnology and pharmaceuticals have long been considered one of the most promising areas for applying artificial intelligence: under favorable circumstances, AI can significantly accelerate the process of scientific discovery — from finding disease mechanisms to developing new drug molecules. Drug development traditionally takes years and requires testing a huge number of hypotheses, most of which are filtered out only at the later, most expensive stages of research.

This is why major AI laboratories are increasingly releasing models tailored to specific scientific and research tasks, rather than universal general-purpose chatbots. For companies like Anthropic, specialized scientific models are both a way to prove the practical usefulness of AI beyond writing text and code, and a way to enter a market with high purchasing power: pharmaceutical companies and research institutes are willing to pay for tools that actually shorten development timelines.

What Anthropic Offers to Scientists

Recognizing the potential of biotech as a direction for AI application, Anthropic offered specialized professionals the Claude Science model — a version of its technologies oriented directly at scientific work. According to the company, the model should help researchers make progress in studying diseases and developing drugs, taking on some of the intellectual burden that previously required months of manual work by scientists with scientific literature, experimental data, and hypotheses.

• Model developer — American startup Anthropic
• Model name — Claude Science
• Target audience — scientists and specialized professionals in biotechnology and pharmaceuticals
• Stated goal — to accelerate the fight against diseases and drug development

Who Else Competes for Scientists as an Audience

Anthropic enters the market for scientific AI tools not alone: in recent years, leading AI laboratories have been competing for the trust of the research community by offering tools for analyzing scientific literature, working with molecular data, and automating routine stages of experiments. For Anthropic, whose reputation is built largely on the reliability and safety of its models, entry into biotech and pharma is particularly logical: errors in this field are more costly than in most other AI applications, which means an emphasis on carefulness becomes a competitive advantage.

Scientists traditionally spend a significant portion of their working time not on the experiments themselves, but on routine intellectual work around them: searching for relevant publications, comparing contradictory results from different laboratories, formulating and screening out hypotheses before conducting expensive experiments. These are precisely the stages that Anthropic expects to ease with Claude Science, freeing up researchers' time for the more creative part of scientific work.

What the Company Has Not Yet Revealed

Anthropic did not provide details about the specific technical capabilities of Claude Science, timelines for full release, or conditions for access by scientific organizations — available information is limited to the announcement of the model and its general purpose. This is typical for the early stage of launching specialized scientific products on the market: laboratories first announce the direction, then gradually reveal detailed capabilities, partnerships with research centers, and conditions of use as the product matures and receives feedback from the first users among scientists.

What This Means

The launch of Claude Science fits into a broader trend: AI laboratories compete not only for chatbot users, but also for the trust of the scientific community by offering specialized tools for the most capital-intensive and socially significant tasks — finding medicines for diseases that are currently not treatable. If such models truly accelerate the cycle of scientific discovery in biotech, the benefits will be felt far beyond the artificial intelligence industry — in clinics and laboratories around the world.